

Sebastiaan Engelborghs

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7326532/sebastiaan-engelborghs-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301
papers

20,697
citations

60
h-index

141
g-index

356
ext. papers

24,885
ext. citations

6.3
avg, IF

5.89
L-index

#	Paper	IF	Citations
301	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009 , 41, 1088-93	36.3	2018
300	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
299	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009 , 41, 1094-9	36.3	1819
298	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011 , 43, 429-35	36.3	1421
297	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. <i>Nature</i> , 2006 , 442, 920-4	50.4	1212
296	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
295	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
294	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. <i>Lancet Neurology, The</i> , 2012 , 11, 54-65	24.1	489
293	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014 , 6, 243ra86	17.5	436
292	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , 2010 , 67, 949-56		344
291	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
290	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
289	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016 , 8, 466-76		256
288	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012 , 6, 419-30	2.3	230
287	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015 , 6, 179	4.1	223
286	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015 , 138, 1327-38	11.2	211
285	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012 , 8, 65-73	1.2	210

284	A pan-European study of the C9orf72 repeat associated with FTL D: geographic prevalence, genomic instability, and intermediate repeats. <i>Human Mutation</i> , 2013 , 34, 363-73	4.7	208
283	The genetics and neuropathology of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2012 , 124, 353-72	14.3	206
282	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2009 , 65, 603-9	9.4	185
281	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008 , 29, 1143-59	5.6	181
280	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
279	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005 , 14, 3281-92	5.6	144
278	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17	1.2	132
277	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 154-163	1.2	129
276	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
275	Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. <i>Archives of Neurology</i> , 2007 , 64, 1436-46		124
274	Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. <i>Neurology</i> , 2015 , 85, 2116-25	6.5	119
273	Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). <i>Neurochemistry International</i> , 2009 , 55, 214-8	4.4	117
272	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. <i>Lancet Neurology</i> , 2015 , 14, 814-822	24.1	95
271	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1461-1469	1.2	95
270	No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> , 2007 , 130, 2320-6	11.2	95
269	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
268	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 274-284	1.2	91
267	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. <i>International Journal of Geriatric Psychiatry</i> , 2005 , 20, 1028-37	3.9	91

266	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. <i>Brain</i> , 2011 , 134, 808-15	11.2	90
265	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017 , 13, 285-295	1.2	88
264	Risk factors for poststroke depression: identification of inconsistencies based on a systematic review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014 , 27, 147-58	3.8	88
263	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	15.2	86
262	Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 1148-51	5.5	85
261	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014 , 128, 397-410	14.3	83
260	Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 1239-50	4.3	82
259	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTL. <i>Brain</i> , 2006 , 129, 841-52	11.2	82
258	Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTL. <i>JAMA Neurology</i> , 2013 , 70, 365-73	17.2	77
257	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid- β Isoforms for Early and Differential Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 813-22	4.3	75
256	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74
255	Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. <i>Neurology</i> , 2009 , 73, 626-32	6.5	73
254	A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid A β 2. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1452-1460	1.2	69
253	Differential role of CSF fatty acid binding protein 3, β synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 52	9	69
252	Biobanking of CSF: international standardization to optimize biomarker development. <i>Clinical Biochemistry</i> , 2014 , 47, 288-92	3.5	68
251	Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. <i>Brain</i> , 2016 , 139, 452-67	11.2	67
250	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017 , 38, 297-309	4.7	66
249	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. <i>Molecular Neurodegeneration</i> , 2012 , 7, 3	19	66

248	Cerebrospinal fluid A β -40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 759-67	4.3	65
247	Loss of psychic self-activation after paramedian bithalamic infarction. <i>Stroke</i> , 2000 , 31, 1762-5	6.7	64
246	The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. <i>Neurochemistry International</i> , 2008 , 52, 1052-60	4.4	63
245	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and F-FDG-PET imaging. <i>NeuroImage: Clinical</i> , 2019 , 22, 101771	5.3	62
244	Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 21	9	61
243	Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. <i>Neurochemistry International</i> , 1999 , 34, 523-30	4.4	61
242	Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. <i>Neurobiology of Aging</i> , 2006 , 27, 285-92	5.6	60
241	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2005 , 20, 70-9	3.9	59
240	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019 , 15, 644-654	1.2	57
239	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <i>Acta Neurologica Belgica</i> , 2017 , 117, 591-602	1.5	57
238	Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. <i>JAMA Neurology</i> , 2015 , 72, 267-75	17.2	55
237	Increased CSF β synuclein levels in Alzheimer's disease: correlation with tau levels. <i>Alzheimer's and Dementia</i> , 2014 , 10, S290-8	1.2	54
236	The Cerebrospinal Fluid A β -42/A β -40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 561-576	4.3	54
235	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010 , 31, 1867-76	5.6	53
234	Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. <i>Neurochemical Research</i> , 2003 , 28, 1145-50	4.6	53
233	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2691-2700	5.6	52
232	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. <i>Human Mutation</i> , 2009 , 30, 1054-61	4.7	52
231	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. <i>JAMA Neurology</i> , 2017 , 74, 445-452	17.2	50

230	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. <i>Neurochemistry International</i> , 2006 , 48, 286-95	4.4	50
229	Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. <i>Journal of the Neurological Sciences</i> , 2014 , 347, 159-66	3.2	48
228	Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2015 , 61, 734-43	5.5	47
227	No correlation between time-linked plasma and CSF A β levels. <i>Neurochemistry International</i> , 2009 , 55, 820-5	4.4	46
226	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A β /A β ratio. <i>Alzheimer's and Dementia</i> , 2017 , 13, 885-892	1.2	44
225	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017 , 17, 170	3.1	44
224	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. <i>Neurobiology of Aging</i> , 2017 , 51, 177.e9-177.e16	5.6	43
223	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 85	9	43
222	Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 819-33	4.3	43
221	Amyloid pathology influences a β 1-42 cerebrospinal fluid levels in dementia with lewy bodies. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 137-46	4.3	42
220	Profiling the dynamics of CSF and plasma A β reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016 , 2, 202-212	6	42
219	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018 , 135, 827-837	14.3	40
218	Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 365-70	3.9	40
217	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 1523-38	4.3	40
216	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1199-1209	4.3	38
215	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. <i>International Journal of Geriatric Psychiatry</i> , 2013 , 28, 265-75	3.9	38
214	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , 2015 , 6, 138	4.1	38
213	No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2011 , 32, 754-5	5.6	38

212	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid τ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
211	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 937-48	4.3	35
210	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017 , 134, 475-487	14.3	34
209	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. <i>Molecular Neurodegeneration</i> , 2015 , 10, 30	19	34
208	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 117-31	4.3	34
207	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 1321-33	4.3	34
206	Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. <i>Acta Clinica Belgica</i> , 2014 , 69, 17-24	1.8	33
205	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 64	9	31
204	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 383-95	4.3	31
203	Identifying frailty risk profiles of home-dwelling older people: focus on sociodemographic and socioeconomic characteristics. <i>Aging and Mental Health</i> , 2017 , 21, 1031-1039	3.5	30
202	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 7	9	30
201	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 100	9	30
200	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015 , 36, 2587-96	5.6	29
199	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015 , 36, 2005.e15-22	5.6	29
198	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 30	9	29
197	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 31	9	29
196	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 19-35	4.3	29
195	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 888-898	6	29

194	Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 807-22	4.3	28
193	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 58	9	27
192	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020 , 139, 1001-1024	14.3	27
191	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018 , 64, 927-937	5.5	27
190	Ataxin-2 polyQ expansions in FTL-ALS spectrum disorders in Flanders-Belgian cohorts. <i>Neurobiology of Aging</i> , 2012 , 33, 1004.e17-20	5.6	27
189	Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1169-75	4.3	27
188	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
187	New insights on the genetic etiology of Alzheimer's and related dementia		25
186	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 864-9	3.9	24
185	Detecting frail, older adults and identifying their strengths: results of a mixed-methods study. <i>BMC Public Health</i> , 2018 , 18, 191	4.1	24
184	Behavioural and neuropsychological correlates of frontal lobe features in dementia. <i>Psychological Medicine</i> , 2006 , 36, 1173-82	6.9	24
183	Functional anatomy, vascularisation and pathology of the human thalamus. <i>Acta Neurologica Belgica</i> , 1998 , 98, 252-65	1.5	24
182	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1437-1449	4.3	23
181	Validation of the Semiquantitative Static SUVR Method for F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1483-1489	8.9	23
180	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
179	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1013-1023	1.2	22
178	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
177	Depressive Symptoms in the Elderly-An Early Symptom of Dementia? A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020 , 11, 34	5.6	22

176	Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 903-9	4.3	22
175	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. <i>Acta Neuropathologica</i> , 2019 , 137, 901-918	14.3	21
174	SolCos model-based individual reminiscence for older adults with mild to moderate dementia in nursing homes: a randomized controlled intervention study. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2016 , 23, 568-575	2.4	21
173	The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 135-41	4.5	20
172	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 33-40	5.6	19
171	Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , 2015 , 19, 247-57	3.5	19
170	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , 2016 , 629, 160-164	3.3	19
169	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 159-170	4.3	19
168	Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. <i>Neurology</i> , 2016 , 86, 2126-33	6.3	19
167	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 51-64	4.3	17
166	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 97-106	4.3	17
165	Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. <i>Journal of Biological Chemistry</i> , 2015 , 290, 4059-74	5.4	16
164	Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , 2015 , 19, 818-28	3.5	16
163	CFAI-Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 941-947	3.9	16
162	F-FDG PET, the early phases and the delivery rate of F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against O-HO PET. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1172-1182	1.2	16
161	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. <i>Revue Neurologique</i> , 2013 , 169, 709-14	3	16
160	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
159	Validation of soluble amyloid- β -precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016 , 137, 112-21	6	15

158	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 1039-43	4.3	15
157	Encephalitis associated with the SARS-CoV-2 virus: A case report. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2020 , 22, 100821	0.5	15
156	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020 , 17, e1003289	11.6	15
155	Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. <i>NeuroImage: Clinical</i> , 2020 , 26, 102243	5.3	14
154	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 73	9	14
153	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. <i>Frontiers in Neuroscience</i> , 2019 , 13, 757	5.1	14
152	Melatonin levels in the Alzheimer's disease continuum: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 52	9	14
151	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. <i>Neurobiology of Aging</i> , 2018 , 69, 292.e7-292.e14	5.6	14
150	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. <i>Neurobiology of Aging</i> , 2018 , 67, 84-94	5.6	13
149	Next Generation Brain Health Depends on Early Alzheimer Disease Diagnosis: From a Timely Diagnosis to Future Population Screening. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 452-3	5.9	13
148	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 1509-1522	4.3	13
147	Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD. <i>Neurology: Genetics</i> , 2016 , 2, e102	3.8	13
146	Exploring Cognitive Frailty: Prevalence and Associations with Other Frailty Domains in Older People with Different Degrees of Cognitive Impairment. <i>Gerontology</i> , 2020 , 66, 55-64	5.5	13
145	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). <i>NeuroImage: Clinical</i> , 2019 , 23, 101846	5.3	12
144	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 79, 131-141	5.6	12
143	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018 , 66, 181.e3-181.e10	5.6	12
142	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLT-DTP brains. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 68	7.3	12
141	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018 , 62, 245.e1-245.e7	5.6	12

140	No added diagnostic value of non-phosphorylated tau fraction (p-tau) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 49	9	11
139	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018 , 69, 293.e9-293.e11	5.6	11
138	Selecting A β isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. <i>Biomarkers in Medicine</i> , 2017 , 11, 169-178	2.3	10
137	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 213-225	4.3	10
136	Impact of frequent cerebrospinal fluid sampling on A β levels: systematic approach to elucidate influencing factors. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 21	9	10
135	Limited engagement in, yet clear preferences for advance care planning in young-onset dementia: An exploratory interview-study with family caregivers. <i>Palliative Medicine</i> , 2019 , 33, 1166-1175	5.5	10
134	Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 1186-95	3.9	10
133	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
132	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 53-58	4.3	10
131	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. <i>Acta Neurologica Belgica</i> , 2017 , 117, 811-819	1.5	9
130	Multicenter Analytical Validation of A β 40 Immunoassays. <i>Frontiers in Neurology</i> , 2017 , 8, 310	4.1	9
129	Headache as only symptom in multiple cervical artery dissection. <i>Headache</i> , 2001 , 41, 509-11	4.2	9
128	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
127	Amyloid- β cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 108	9	9
126	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 324-333	3.9	9
125	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 373-381	4.3	9
124	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 989-1001	4.3	8
123	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019 , 497, 204-211	6.2	8

122	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. <i>Neuroscience Research Communications</i> , 2000 , 26, 193-206		8
121	A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease. <i>PLoS ONE</i> , 2017 , 12, e0189155	3.7	8
120	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. <i>Acta Neurologica Belgica</i> , 2015 , 115, 547-55	1.5	7
119	The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. <i>Journal of the Neurological Sciences</i> , 2012 , 322, 197-9	3.2	7
118	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021 , 28, 2147-2155	6	7
117	Techniques, Contraindications, and Complications of CSF Collection Procedures 2015 , 35-57		7
116	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 25	7.3	7
115	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1151-1159	4.3	6
114	Extended FTL D pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 7	9	6
113	Randomized controlled trial to evaluate a prevention program for frail community-dwelling older adults: a D-SCOPE protocol. <i>BMC Geriatrics</i> , 2018 , 18, 194	4.1	6
112	Callosal circularity as an early marker for Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018 , 19, 516-526	5.3	5
111	Severe bilateral subdural hematomas as a complication of diagnostic lumbar puncture for possible Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017 , 152, 95-96	2	4
110	Impact of hearing loss and vestibular decline on cognition in Alzheimer's disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECKO). <i>BMJ Open</i> , 2020 , 10, e039601	3	4
109	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4
108	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
107	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
106	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2021 , 12, 707580	5	4
105	Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. <i>Arzneimittelforschung</i> , 1998 , 48, 713-6		4

104	Comparing Advance Care Planning in Young-Onset Dementia in the USA vs Belgium: Challenges Partly Related to Societal Context. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 851-857	5.9	3
103	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2021 , 80, 1629-1642	4.3	3
102	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 712545	5.3	3
101	Meanings of Care Convoys: The Structure, Function, and Adequacy of Care Networks Among Frail, Community-Dwelling Older Adults. <i>Qualitative Health Research</i> , 2020 , 30, 583-597	3.9	3
100	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports: A Systematic Review. <i>Neurology</i> , 2021 , 96, 705-715	6.5	3
99	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 104, 105.e1-105.e6	5.6	3
98	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 623-639	4.3	3
97	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. <i>Neurobiology of Aging</i> , 2021 , 106, 307.e1-307.e7	5.6	3
96	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021 , 108, 99-109	5.6	3
95	Apraxic agraphia following thalamic damage: Three new cases. <i>Brain and Language</i> , 2015 , 150, 153-65	2.9	2
94	[P2B63]: EARLY FRAME 18F-AV45 AND 18F-FDG-PET AS PROXIES OF CBF: COMPARISON TO 15O-H2O PET DATA 2017 , 13, P763-P764		2
93	5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 1108-9	3.9	2
92	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. <i>Neurobiology of Aging</i> , 2021 , 97, 145.e1-145.e4	5.6	2
91	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2
90	Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. <i>Acta Neurologica Belgica</i> , 2003 , 103, 99-102	1.5	2
89	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
88	3xTg Alzheimer's disease mice are more susceptible to induced seizures. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044096	1.2	1
87	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047209	1.2	1

86	A family-based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. <i>Alzheimers and Dementia</i> , 2020 , 16, e047212	1.2	1
85	P4-232: A monoclonal antibody-based elisa for neurogranin 2015 , 11, P869-P869		1
84	[P4075]: THE MAPT P.ARG406TRP IS A FOUNDER MUTATION IN BELGIUM AND PRESENTS WITH AN ALZHEIMER DISEASE DEMENTIA-LIKE PHENOTYPE 2017 , 13, P1286-P1286		1
83	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study 2015 , 11, P297-P297		1
82	P4-249: Admetrix: A new method for atrophy quantification in Alzheimer's disease 2015 , 11, P876-P876		1
81	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions 2015 , 11, P384-P384		1
80	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease 2020		1
79	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 746982	5.3	1
78	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
77	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. <i>Acta Neurologica Belgica</i> , 2020 , 120, 1157-1163	1.5	1
76	Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review. <i>Ear and Hearing</i> , 2021 , 42, 1119-1126	3.4	1
75	P1-407: Cognitive Frailty: A New Domain Added to The Comprehensive Frailty Assessment 2016 , 12, P590-P590		1
74	O1-11-02: Combination of Cerebrospinal Fluid H-FABP and Core Alzheimer's Disease Biomarkers Improves the Differential Diagnosis of Neurodegenerative Disorders 2016 , 12, P201-P202		1
73	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 99, 100.e17-100.e23	5.6	1
72	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021 , 80, 313-324	3.1	1
71	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline. <i>Journal of Alzheimers Disease</i> , 2021 , 83, 693-704	4.3	1
70	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
69	A qualitative study with people with young-onset dementia and their family caregivers on advance care planning: A holistic, flexible, and relational approach is recommended.. <i>Palliative Medicine</i> , 2022 , 2692163221090385	5.5	1

68	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 48	5.6	o
67	iPSC-derived cortical neurons to study sporadic Alzheimer disease: a transcriptome comparison with post-mortem brain samples.. <i>Toxicology Letters</i> , 2021 , 356, 89-89	4.4	o
66	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2021 , 156, 105421	7.5	o
65	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	o
64	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12314	5.2	o
63	Biomarker counseling, disclosure of diagnosis, and follow-up in patients with mild cognitive impairment: A European survey of EADC centers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039026	1.2	
62	Recessive missense variants in VWA2 increase risk of developing Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039791	1.2	
61	ABCA7 mutations are major contributors to Alzheimer's disease in Belgian patients. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040227	1.2	
60	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041513	1.2	
59	Cerebrospinal fluid amyloid status and affective symptoms in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041961	1.2	
58	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042739	1.2	
57	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045853	1.2	
56	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimer's Disease Studies 2016 , 12, P1075-P1076		
55	P3-209: Impact of Biomarkers On Diagnostic Confidence in Clinical Assessment of Patients with Suspected Alzheimer's Disease and High Diagnostic Uncertainty: An EADC Study 2016 , 12, P904-P905		
54	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE 2014 , 10, P322-P323		
53	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium 2015 , 11, P253-P253		
52	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease 2015 , 11, P296-P297		
51	P4-248: Resting state functional MRI as a possible biomarker for Alzheimer's disease: An innovative approach for robust extraction of the default mode network 2015 , 11, P876-P876		

- 50 [P4069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLY-ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA **2017**, 13, P1284-P1284
- 49 [P1037]: DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, SYNNUCLEIN AND ALZHEIMER'S DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER'S DEMENTIA **2017**, 13, P334-P335
- 48 [P4039]: FDG-PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER'S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS **2017**, 13, P1366-P1367
- 47 [P1089]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2017**, 13, P361-P362
- 46 [P1087]: CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING **2017**, 13, P414-P414
- 45 [P2016]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER'S DISEASE **2017**, 13, P651-P651
- 44 [P2011]: AMYLOID- β 2 (A β 2) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION **2017**, 13, P690-P691
- 43 [O20305]: DELETERIOUS ABCA7 MUTATIONS CONTRIBUTE TO EARLY-ONSET ALZHEIMER'S DISEASE AND ARE SUBJECT TO TRANSCRIPT RESCUE MECHANISMS **2017**, 13, P589-P590
- 42 P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients **2015**, 11, P626-P626
- 41 P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease **2015**, 11, P854-P854
- 40 O1-04-04: ANALYSIS OF SQSTM1 IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE **2014**, 10, P135-P136
- 39 O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease **2010**, 6, S73-S74
- 38 Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap. *Frontiers in Neuroscience*, **2021**, 15, 781322 5.1
- 37 P2-299: Brief Neuropsychological Screening Tests for the Detection of Alzheimer's Disease in an Early Phase: A Systematic Review **2016**, 12, P748-P748
- 36 P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline **2016**, 12, P1059-P1061
- 35 P4-194: Blood Flow Independent Quantification of [18F]-AV45 PET Using Model-Based Kinetics With a Metabolite-Corrected Arterial Input Function **2016**, 12, P1097-P1098
- 34 P1-176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration **2016**, 12, P471-P471
- 33 P1-320: Volumetric Brain MRI of Different Regions, Including The Hippocampus, in The Alzheimer's Disease Spectrum: A Systematic Review **2016**, 12, P547-P548

- 32 P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis **2016**, 12, P672-P673
- 31 P3-258: Resting State Functional Mri in Alzheimer's Disease: an Innovative Approach for Robust Extraction of the Default Mode Network **2016**, 12, P930-P930
- 30 P4-120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTLD-GRN Mutation Carriers **2016**, 12, P1058-P1059
- 29 O4-09-03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration **2016**, 12, P354-P355
- 28 P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium **2016**, 12, P467-P468
- 27 P4-314: Discordance Between Amyloid-PET and CSF Amyloid- β for Diagnosing Alzheimer's Disease in a Clinical Setting **2016**, 12, P1154-P1154
- 26 P4-322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimer's Disease **2016**, 12, P1157-P1157
- 25 P4-324: Plasma Neurofilament Light Concentration Predicts Long-Term Outcome an Acute Stroke **2016**, 12, P1158-P1158
- 24 P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE **2019**, 15, P1515-P1516
- 23 ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS **2019**, 15, P1626-P1627
- 22 IC-P-130: ICOBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER'S DISEASE **2019**, 15, P107-P108
- 21 Diagnostic Evaluation of Dementia **2021**, 31-55
- 20 Lumbar Puncture: Consensus Guidelines. *Neuromethods*, **2021**, 129-135 0.4
- 19 P2-270: INCREASED CSF AMYLOID- β -38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY **2018**, 14, P780-P781
- 18 P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161
- 17 P2-228: PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA **2018**, 14, P755-P756
- 16 O4-01-01: IN-DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE **2018**, 14, P1400-P1400
- 15 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204

- 14 P3-128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA **2018**, 14, P1116-P1117
- 13 P3-409: PERFORMANCE EVALUATION OF AUTOMATIC BRAIN MRI SUBSTRUCTURE SEGMENTATION WITH ICOBRAIN **2018**, 14, P1260-P1262
- 12 F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION **2018**, 14, P201-P202
- 11 F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A β APOE ϵ AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P201-P201
- 10 P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P895-P896
- 9 F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P202-P204
- 8 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 7 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 6 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 5 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 4 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 3 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 2 Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study **2020**, 17, e1003289
- 1 Biological and genetic markers of sporadic Alzheimer's disease. *Acta Medica Okayama*, **2001**, 55, 55-63 0.5